Where lipase is permitted, and what the file must show
Lipase from Candida rugosa is a food enzyme, not a food additive. In the EU and the UK the authorised list is still in transition; in the US the route is a GRAS conclusion, and the notice that covers this source is use-specific. The file has to show the source, the use, the limits and the label wording for each market, because permission, purity, labelling and claims are four different questions.
Permission, contaminant limits, label wording and claims are four separate checks, and each market answers them with a different instrument.
Four checks, not one
The first question is whether the enzyme may be used in the intended food process in that market. The second is whether the preparation meets the contaminant and microbiological limits that apply to the finished food. The third is how the material is described on the label, including the carrier. The fourth is what the brand says about it.
Lipase is handled as a food enzyme, not as an additive, so the authorisation route, the labelling rules and the documents are different. The source organism and the production strain belong in the file as well: “lipase” describes an activity, not a production process, and two preparations with the same activity can come from different organisms.
European Union
Food enzymes fall under Regulation (EC) No 1332/2008. The regulation requires an enzyme to be included in the Union list before it is placed on the market or used in food, but the Union list has not yet been adopted. Article 24 provides that, until the Union list applies, national provisions on the placing on the market and use of food enzymes continue to apply in the Member States. As of November 2026 the list is still pending; check the current text before a launch.
The Commission maintains a Register of food enzyme applications, and the file should show the entry that covers this enzyme and its intended use. EFSA evaluates the dossier, including the source organism, the production process, the use levels and the removal of the production organism. National rules differ, so the Member State of sale has to be named in the check, not only “the EU”.
A supplier should not describe a C. rugosa lipase as “EU approved” while the Union list is pending; the accurate statement is that it is placed on the market under the applicable national provisions, with the register entry and application status in the file.
United States
Lipase from C. rugosa is not listed in 21 CFR Part 173 for this source. The Part 173 entry for a lipase, §173.140, covers an esterase-lipase from Mucor miehei, which is a different enzyme and a different production organism. The US route for the C. rugosa material is a GRAS conclusion.
GRAS Notice 81, filed by Amano Enzyme in 2001, covers lipase from C. rugosa for use on fats and oils to produce fatty acids or glycerides at up to 1% of the weight of the fat or oil, and for the esterification of fatty acids to produce glycerides at up to 1% of the weight of the fatty acids. FDA responded that it had no questions. That response is not an approval, and the notice is use-specific: a use outside those conditions needs its own GRAS basis. For a dietary supplement, the brand needs a GRAS basis or a new dietary ingredient notification for its intended use.
Labelling follows the processing-aid rule. Under 21 CFR 101.100(a)(3), a processing aid that has no technical effect in the finished food is exempt from ingredient declaration; an enzyme that remains active and functional in the finished food is not. The brand decides the label.
United Kingdom
Great Britain applies assimilated Regulation (EC) No 1332/2008. The FSA and FSS maintain a register of regulated-product authorisations, and the domestic list of food enzymes was not yet established at this review. Until initial authorisations are made, food enzymes under the assimilated regulation do not need approval before use. The 2025 reform changed how future authorisations take effect, not the status of existing enzymes.
Northern Ireland follows the EU regime, so a GB check and an NI check are separate exercises.
Limits and where they come from
| Parameter | Catalog limit | Market note |
|---|---|---|
| Lead | ≤3 mg/kg | EU food supplements: 3.0 mg/kg as sold |
| Cadmium | ≤1 mg/kg | EU food supplements: 1.0 mg/kg as sold |
| Mercury | ≤0.1 mg/kg | EU food supplements: 0.10 mg/kg as sold |
| Arsenic | ≤2 mg/kg | No general EU maximum for this matrix; the specification sets the limit |
| Microbiology | APC ≤10,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent | General food-safety duty; the customer specification may be tighter |
| Loss on drying | ≤8.0% | Quality parameter; it also sets the activity basis |
The EU ceilings apply to the food supplement as sold, not to the enzyme powder. The ingredient limit has to be set so that the finished product stays under the ceiling. The brand does that calculation; the COA is an input, not a substitute.
What the label and the claim may say
No disease-related claim is made for this material, and the technical pages describe the specification and the file, not a physiological effect. “Lipase activity ≥100,000 LU/g” is a statement about the preparation, not a health claim.
A claim about the finished food belongs to the brand and must be authorised in the market where it is made: the EU health-claims regulation, the US supplement rules and the retained UK regime each set their own test. The enzyme file supports identity, activity and purity; it does not support a claim about what the finished product does to the body.
The document pack
- Specification with the unit definition and the assay conditions.
- Batch COA with the lot result and the release limit on separate lines.
- Technical data sheet with the activity, solubility, pH and packing.
- Safety data sheet with the dust and exposure controls.
- Allergen statement covering the enzyme source and the carrier.
- GMO statement for the production organism and the raw materials.
- Origin and production-strain record.
- Carrier and composition statement.
- Stability summary for the grade and the pack.
Compliance checklist
| Check | Evidence |
|---|---|
| Market and intended use named | Regulatory basis memo for that use, not only for the substance |
| Source organism and strain documented | Origin record and production-strain statement |
| Enzyme status confirmed | EU register entry, US GRAS basis or UK register position, as applicable |
| Contaminants within the destination limit | Batch COA and, where needed, a third-party report |
| Carrier and allergen checked | Composition statement and label artwork |
| Label wording checked | Activity, unit, carrier and storage statement on the pack |
| Claims reviewed | Claim file owned by the brand, not by the supplier |
| Document pack complete | The nine documents listed above, in the version released with the lot |
The catalog position is on the lipase product page; the release parameters are on the COA page, the source and activity evidence is on the identity page, and the market frameworks are summarised in the EU, US and UK regulatory notes. The release workflow is described on the quality page.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation